PHIO on Nasdaq

Phio Pharmaceuticals Corp.

American pharmaceutical preparations company based in King Of Prussia. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with JUPITER NEUROSCIENCES, INC., SKINVISIBLE, INC. or BIOADAPTIVES, INC., or pick any stock.

  • TickerPHIO on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersMarlborough, United States2
  • Incorporated inDE3
  • Business address411 Swedeland Road, Suite 23-1080, King Of Prussia, Pa 194063
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300KOGMLSPLDVHR522
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressc/o PARACORP INCORPORATED, 2140 S DUPONT HWY, 19934 Camden, United States2
  • Registered withDivision of Corporations, Department of State, 50355732

See how the biggest companies compare on our leaderboards

Phio Pharmaceuticals Corp. (“ Phio ,” “ we ,” “ our ” or the “ Company ”) is a clinical stage biopharmaceutical company whose proprietary INTASYL® small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. We are developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. We are committed to discovering and developing innovative cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment and a single reportable segment.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-100.0%Revenue growth, 20205
-67.6%Return on equity6
0.02×Debt to equity7
-$8.8MFree cash flow7

Financial statements

Revenue5$0 in 2020
0$10.0K$20.0K$30.0K2019: $21.0K$21.0K20192020: $0$02020
Operating income57-$8.8M in 2020−2% since 2019
-$10.0M-$7.5M-$5.0M-$2.5M02019: -$9.0M-$9.0M20192020: -$8.8M-$8.8M2020−2%
Net income57-$8.8M in 2020−1% since 2019
-$10.0M-$7.5M-$5.0M-$2.5M02019: -$8.9M-$8.9M20192020: -$8.8M-$8.8M2020−1%

Every line of the income statement as filed: the last 2 fiscal years, latest first.10

Period ending2025-12-312024-12-31
Research and development$4.6M$3.6M
General and administrative$4.6M$3.7M
Total operating expenses$9.2M$7.4M
Operating loss-$9.2M-$7.4M
Interest income, net$520.0K$231.0K
Other income, net$2.0K$6.0K
Net loss-$8.7M-$7.2M
Basic and diluted (in dollars per share)-$1.45-$9.08
Basic and diluted (in shares)6.0M shares787.5K shares

Compare Phio Pharmaceuticals Corp. with another company

Leadership

Who has led Phio Pharmaceuticals Corp., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Geert Cauwenbergh2013–2019
  2. Gerrit Dispersyn2019–2022
  3. Robert J. Bitterman2023–now

Chair

  1. Robert J. Bitterman2022–now

President

  1. Geert Cauwenbergh2013–2018
  2. Gerrit Dispersyn2019–2022
  3. Robert J. Bitterman2023–2024

Chief financial officer

  1. Robert M. Infarinato2024
  2. Lisa Cabott Carson2026–now

Chief operating officer

  1. Gerrit Dispersyn2019
201520202025
Board members and other officers (15)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorCurtis A. Lockshin, Ph.D. named Dec 19, 2023 to Nov 12, 202532
  • DirectorJonathan A. Freeman named Nov 23, 2022 to Nov 12, 202532

Former names

  • RXi Pharmaceuticals CorpOct 25, 2011 to Nov 14, 20183

Timeline

  1. Feb 22, 2023New chief executive Robert J. Bitterman becomes CEO11
  2. Mar 5, 2019New chief executive Gerrit Dispersyn becomes CEO12
  3. Mar 1, 2013New chief executive Geert Cauwenbergh becomes CEO13
  4. Sep 8, 2011Founded Phio Pharmaceuticals Corp. is founded2

Filings

299 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 85 major events, 84 insider forms, 19 large holders, 12 private raises, 78 other. The latest 20:

  1. Oct 13, 20268-K EDGAR
  2. Sep 30, 20264 EDGAR
  3. Sep 29, 20264 EDGAR
  4. Sep 29, 20264 EDGAR
  5. Sep 29, 20264 EDGAR
  6. Sep 28, 2026S-8 EDGAR
  7. Sep 28, 20268-K EDGAR
  8. Sep 25, 20264 EDGAR
  9. Sep 23, 20264 EDGAR
  10. Sep 16, 20264 EDGAR
  11. Sep 15, 20264 EDGAR
  12. Sep 15, 20264 EDGAR
  13. Sep 14, 20268-K EDGAR
  14. Aug 20, 20264 EDGAR
  15. Aug 19, 20264 EDGAR
  16. Aug 14, 2026ARS ANNUAL REPORT EDGAR
  17. Aug 14, 2026DEFA14A ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS EDGAR
  18. Aug 14, 2026DEF 14A EDGAR
  19. Aug 6, 20268-K EDGAR
  20. Aug 6, 202610-Q EDGAR

The 299 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

32 open-market trades by officers, directors and large owners since October 2021: 32 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 29, 2026Plott Ronald ToddDirectorBuy5,000$1.04$5.2KForm 4
Sep 28, 2026Plott Ronald ToddDirectorBuy5,000$1.03$5.2KForm 4
Sep 24, 2026BRADFORD PATRICIA ADirectorBuy6,500$1.01$6.6KForm 4
Sep 22, 2026Bitterman Robert JChairman, Pres. & CEOBuy2,000$1.03$2.1KForm 4
Sep 15, 2026BRADFORD PATRICIA ADirectorBuy12,000$1.03$12.4KForm 4
Aug 19, 2026Plott Ronald ToddDirectorBuy15,000$1.14$17.1KForm 4
Aug 18, 2026Bitterman Robert JChairman, Pres. & CEOBuy10,000$1.06$10.6KForm 4
Jun 26, 2026Bitterman Robert JChairman, Pres. & CEOBuy10,000$0.99$9.9KForm 4
Dec 31, 2025Bitterman Robert JChairman, Pres. & CEOBuy5,000$1.03$5.2KForm 4
Dec 23, 2025Bitterman Robert JChairman, Pres. & CEOBuy5,000$1.02$5.1KForm 4
Nov 21, 2025Bitterman Robert JChairman, Pres. & CEOBuy5,000$1.14$5.7KForm 4
Nov 18, 2025Bitterman Robert JChairman, Pres. & CEOBuy5,000$1.27$6.3KForm 4
Jun 10, 2025Bitterman Robert JChairman, Pres. & CEOBuy2,000$2.42$4.8KForm 4
Jun 10, 2025Ferrara Robert LDirectorBuy2,500$2.42$6.0KForm 4
Jun 9, 2025Bitterman Robert JChairman, Pres. & CEOBuy1,500$2.75$4.1KForm 4
May 22, 2025Bitterman Robert JChairman, Pres. & CEOBuy1,200$1.78$2.1KForm 4
May 21, 2025Bitterman Robert JChairman, Pres. & CEOBuy3,000$1.77$5.3KForm 4
May 20, 2025Ferrara Robert LDirectorBuy2,500$1.82$4.5KForm 4
Jun 7, 2024Bitterman Robert JChairman, Pres. & CEOBuy1,000$0.74$740Form 4
Jun 6, 2024Bitterman Robert JChairman, Pres. & CEOBuy1,000$0.75$750Form 4

All 32 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 4, 2025Raised $1.4 million in a private offering of securities Form D: $25.9 million offered in all Form D
  2. Jul 28, 2025Raised $232,149 in a private offering of securities Form D: $5.1 million offered in all Form D
  3. Jan 17, 2025Raised $152,500 in a private offering of securities Form D: $3.7 million offered in all Form D
  4. Jan 15, 2025Raised $208,334 in a private offering of securities Form D: $5 million offered in all Form D
  5. Jan 14, 2025Raised $265,918 in a private offering of securities Form D: $6.4 million offered in all Form D
  6. Dec 24, 2024Raised $30,000 in a private offering of securities Form D: $480,000 offered in all Form D
  7. Dec 20, 2024Raised $54,649 in a private offering of securities Form D: $1.3 million offered in all Form D
  8. Jul 11, 2024Raised $136,322 in a private offering of securities Form D: $6.4 million offered in all Form D
  9. Dec 8, 2023Raised $532,563 in a private offering of securities Form D: $5.4 million offered in all Form D
  10. Jun 2, 2023Raised $3 million in a private offering of equity Form D: $10.9 million offered in all Form D
  11. Apr 20, 2023Raised $4 million in a private offering of securities Form D: 3 investors so far Form D
  12. Nov 16, 2022Raised $1,750 in a private offering of equity Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Jane Street Group, LLC117,755$120.7K0.0%−1,434
Geode Capital Management, LLC114,574$117.4K0.0%−32,680
Vanguard Capital Management LLC94,262$96.6K0.0%+14,409
Nomura Asset Management International Inc.50,000$51.0K0.0%New
Cetera Investment Advisers47,500$48.7K0.0%+2,500
Citadel Advisors LLC47,150$48.3K0.0%New
Vanguard Fiduciary Trust Co38,169$39.1K0.0%No change
Northern Trust Corp27,768$28.5K0.0%+4,010
Two Sigma Investments, LP21,501$22.0K0.0%−10,994
XTX Topco Ltd18,475$18.9K0.0%−6,393
Bridgeway Capital Management, LLC12,000$12.3K0.0%New
Citigroup Inc11,605$11.9K0.0%+10,580
Captrust Financial Advisors10,000$10.2K0.0%No change
Tower Research Capital LLC (TRC)6,206$6.4K0.0%−1,414
Morgan Stanley6,000$6.2K0.0%No change
UBS Group AG5,387$5.5K0.0%−21,600
Osaic Holdings, Inc.2,000$2.1K0.0%No change
Spire Wealth Management1,990$2.0K0.0%−10
SBI Securities Co., Ltd.1,247$1.3K0.0%+23
Barclays PLC231$2370.0%New
Assetmark, Inc110$1130.0%No change
Hrt Financial LP13,182$130.0%−21,550
Activest Wealth Management9$90.0%No change
Caitong International Asset Management Co., Ltd6$60.0%+3

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36